bioAffinity says CyPath Lung test sales more than double through Q3 2026
BIAF•bioAffinity Technologies said CyPath Lung test sales rose more than 100% through Q3 2026, with 1,620 tests delivered versus 775 a year earlier. Ordering physicians increased 89% in Q3, and a distribution agreement aims to broaden access in government healthcare.
1. Test sales increase
bioAffinity Technologies reported that CyPath Lung test sales rose more than 100% through Q3 2026 compared with the prior-year period. The company delivered 1,620 tests, up from 775 a year earlier. Ordering physicians increased 89% in Q3 versus Q3 2025, while physicians who ordered through Q3 2025 lifted test volume 48% year over year. A distribution agreement with Veteran-Owned AvMEDICAL targets broader access in government healthcare, including the Department of Veterans Affairs.
